GSK's RSV Vaccine Arexvy Approved for Adults by European Commission
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: NASDAQ.COM
- Vaccine Approval: GSK's Arexvy vaccine has been approved by the European Commission for use in adults aged 18 and older, marking the first authorization of an RSV vaccine in the European Economic Area, which is expected to significantly increase adult RSV vaccination rates.
- Indication Expansion: The approval extends Arexvy's use beyond adults aged 60 and older to include those aged 50 to 59 at increased risk, thereby broadening the vaccine's potential market and addressing a wider public health need.
- Market Impact: With the vaccine's rollout, GSK is poised to capture a larger share of the adult vaccine market, enhancing its competitive position in respiratory disease prevention while generating substantial revenue growth for the company.
- Public Health Strategy: This move aligns with the growing global demand for RSV vaccines, which is expected to improve prevention outcomes for adult respiratory diseases and elevate overall public health standards.
Analyst Views on GSK
Wall Street analysts forecast GSK stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GSK is 38.72 USD with a low forecast of 20.15 USD and a high forecast of 55.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
1 Buy
2 Hold
3 Sell
Moderate Sell
Current: 50.800
Low
20.15
Averages
38.72
High
55.60
Current: 50.800
Low
20.15
Averages
38.72
High
55.60
About GSK
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
